AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21645007 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-containing RBC transfusions
Number of subjects: 0
Study 21645007 — intervention group
Group type: EXPERIMENTAL
Intervention: PLT transfusions
Number of subjects: 0
Study 18056855 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 168
Study 18056855 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment
Number of subjects: 168
Study 16929421 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg oral misoprostol every 4 h (treatment group 1)
Number of subjects: 100
Study 16929421 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg oral misoprostol every 4 h (treatment group 2)
Number of subjects: 100
Study 16929421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin B6 50 mg, control)
Number of subjects: 100
Study 12922104 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of Avaxim pediatric hepatitis A vaccine given at 6 months of age (Group 2)
Number of subjects: 108
Study 12922104 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of Avaxim pediatric hepatitis A vaccine given 2 weeks after routine vaccinations (Group 1)
Number of subjects: 108
Study 10831287 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombopoietin (TPO)
Number of subjects: 0
Study 8775591 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month therapeutic community (TC) program
Number of subjects: 495
Study 8775591 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month relapse prevention (RP) program
Number of subjects: 495
Study 8775591 — intervention group
Group type: COMPARATOR
Intervention: 6-month therapeutic community (TC) program
Number of subjects: 495
Study 8775591 — intervention group
Group type: COMPARATOR
Intervention: 3-month relapse prevention (RP) program
Number of subjects: 495
Study 1294401 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (10,000 IU i.m. on first diagnosis of pregnancy, 5000 IU twice weekly to week 12, then once weekly to week 16)
Number of subjects: 75
Study 1294401 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical ampoulage)
Number of subjects: 75
Study 1294401 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (for patients with no defined cause for habitual abortion)
Number of subjects: 75
Study 1294401 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for patients with no defined cause for habitual abortion)
Number of subjects: 75
Study 1294401 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG and Placebo
Number of subjects: 75
Study 6536512 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphaxalone
Number of subjects: 7
Study 6536512 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphadolone
Number of subjects: 7
Study 31335349 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based protein assay
Number of subjects: 0
Study 31335349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no blood-based protein assay)
Number of subjects: 0
Study 29795527 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil once a day
Number of subjects: 63
Study 29795527 — intervention group
Group type: COMPARATOR
Intervention: 20 mg tadalafil on-demand (four times a month)
Number of subjects: 63
Study 27255448 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulator (group N, n = 60)
Number of subjects: 120
Study 27255448 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (group U, n = 60)
Number of subjects: 120
Study 23322261 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexander Technique (AT) with 12 weekly home-based lessons in addition to usual care
Number of subjects: 120
Study 23322261 — intervention group
Group type: COMPARATOR
Intervention: Usual care from Guide Dogs NSW/ACT
Number of subjects: 120
Study 23071635 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (50 mg transdermal administration)
Number of subjects: 91
Study 23071635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 20191485 — intervention group
Group type: COMPARATOR
Intervention: Anti-tumor necrosis factor therapy (exact dosage and duration not specified)
Number of subjects: 32
Study 20191485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomous scoring method for posterior element inflammation
Number of subjects: 32
Study 20191485 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI evaluation of posterior elements
Number of subjects: 32
Study 18569128 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation & Sports (R&S) + Active after Rehabilitation (AaR)
Number of subjects: 887
Study 18569128 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 887
Study 16046345 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training for nine weeks followed by six weeks of detraining
Number of subjects: 21
Study 16046345 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training followed by six weeks of detraining
Number of subjects: 21
Study 12071689 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated presentations of the same food
Number of subjects: 35
Study 12071689 — intervention group
Group type: COMPARATOR
Intervention: Variety of isocaloric food
Number of subjects: 35
Study 12071689 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 35
Study 10618938 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone
Number of subjects: 18
Study 10618938 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 18
Study 7567422 — intervention group
Group type: EXPERIMENTAL
Intervention: Flotation REST (floating in a commercially produced tank)
Number of subjects: 7
Study 7567422 — intervention group
Group type: COMPARATOR
Intervention: In-bed REST (lying alone on a bed in an isolation box)
Number of subjects: 7
Study 7567422 — intervention group
Group type: EXPERIMENTAL
Intervention: Flotation REST
Number of subjects: 7
Study 7567422 — intervention group
Group type: COMPARATOR
Intervention: In-bed REST
Number of subjects: 7
Study 1827394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive foot care intervention
Number of subjects: 0
Study 7097422 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplement isolated from mature human milk, increasing protein content by 0.8 gm/dl
Number of subjects: 18
Study 7097422 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented group
Number of subjects: 18
Study 7097422 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of more than 3 gm/kg/day
Number of subjects: 18
Study 7097422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (supplemented and unsupplemented)
Number of subjects: 18
Study 31588477 — intervention group
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Number of subjects: 120
Study 31588477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold spray
Number of subjects: 120
Study 31588477 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 29578832 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily motivational text messages, additional texted tips in response to keywords, and weekly study questions
Number of subjects: 150
Study 29578832 — intervention group
Group type: COMPARATOR
Intervention: Weekly study questions only
Number of subjects: 150
Study 26855121 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Change Approach (SCA)
Number of subjects: 320
Study 26855121 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 320
Study 24845190 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-life observation of stressor
Number of subjects: 362
Study 24845190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate observer-target dyads
Number of subjects: 362
Study 24845190 — intervention group
Group type: COMPARATOR
Intervention: Virtual observation modality
Number of subjects: 362
Study 24845190 — intervention group
Group type: COMPARATOR
Intervention: Stranger observation
Number of subjects: 362
Study 23018233 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 50 mg once daily
Number of subjects: 1110
Study 23018233 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 1110
Study 20844075 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Concord grape juice (7 mL · kg⁻¹ · d⁻¹)
Number of subjects: 64
Study 20844075 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo beverage
Number of subjects: 64
Study 20844075 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Concord grape juice
Number of subjects: 64
Study 17270515 — intervention group
Group type: EXPERIMENTAL
Intervention: New orthosis
Number of subjects: 27
Study 17270515 — intervention group
Group type: EXPERIMENTAL
Intervention: New orthosis after 3 weeks of familiarization
Number of subjects: 27
Study 16094738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential radical radiotherapy and cisplatin-based chemotherapy
Number of subjects: 288
Study 16094738 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy alone
Number of subjects: 288
Study 12084743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with intraoperative antimetabolites (5‐fluorouracil 25 mg/ml, mitomycin C 0.2 mg/ml and 0.4 mg/ml)
Number of subjects: 48
Study 12084743 — intervention group
Group type: COMPARATOR
Intervention: Viscocanalostomy with intraoperative intracanalicular Healonid GV injection
Number of subjects: 48
Study 12084743 — intervention group
Group type: COMPARATOR
Intervention: Viscocanalostomy with balanced saline solution
Number of subjects: 48
Study 12084743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 48
Study 9448865 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission structured education
Number of subjects: 50
Study 9448865 — intervention group
Group type: COMPARATOR
Intervention: Postadmission unstructured education
Number of subjects: 50
Study 7887720 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous donation (group 1)
Number of subjects: 348
Study 7887720 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 348
Study 7887720 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with three units of predonated autologous blood (group 1)
Number of subjects: 348
Study 7887720 — intervention group
Group type: EXPERIMENTAL
Intervention: Other blood conservation measures (both groups)
Number of subjects: 348
Study 2296627 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (200 mg t.i.d.)
Number of subjects: 24
Study 2296627 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg b.i.d.)
Number of subjects: 24
Study 2296627 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (0.6 g/l blood alcohol concentration)
Number of subjects: 24
Study 340155 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 7036
Study 340155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7036
Study 31784904 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive-Servo Ventilation (ASV)
Number of subjects: 749
Study 31090488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg mixed in juice, administered 30 minutes before procedure)
Number of subjects: 52
Study 31090488 — intervention group
Group type: COMPARATOR
Intervention: Placebo (only juice)
Number of subjects: 52
Study 28237604 — intervention group
Group type: EXPERIMENTAL
Intervention: High velocity resistance training (HVRT) at 240°/s
Number of subjects: 26
Study 28237604 — intervention group
Group type: COMPARATOR
Intervention: Low velocity resistance training (LVRT) at 75°/s
Number of subjects: 26
Study 26347966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal, dual-component onlay mesh
Number of subjects: 70
Study 26347966 — intervention group
Group type: COMPARATOR
Intervention: Traditional stoma (Control)
Number of subjects: 70
Study 26347966 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 26347966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 70
Study 23631560 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol matricectomy (PM)
Number of subjects: 120
Study 23631560 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail-splinting using a flexible tube (FT)
Number of subjects: 120
Study 23631560 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 21320258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 124
Study 21320258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 19165681 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 200
Study 19165681 — intervention group
Group type: COMPARATOR
Intervention: Routine feeding
Number of subjects: 200
Study 17102644 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate (MCC) vaccines administered at the same time as DT/Td boosters
Number of subjects: 1754
Study 17102644 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate (MCC) vaccines administered a month before or after DT/Td boosters
Number of subjects: 1754
Study 17102644 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of analgesics/antipyretic medication
Number of subjects: 1754
Study 17102644 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects post-vaccination
Number of subjects: 1754
Study 17102644 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC vaccines under the above schedules
Number of subjects: 1754
Study 15603004 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Employment Supports (CES) model
Number of subjects: 121
Study 15603004 — intervention group
Group type: COMPARATOR
Intervention: Standard vocational counseling
Number of subjects: 121
Study 11269570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine L-tartrate 2 mg administered with a standardized medium-fat breakfast
Number of subjects: 23
Study 11269570 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine L-tartrate 2 mg administered on an empty stomach
Number of subjects: 23
Study 10998085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine (1 mg h‐1)
Number of subjects: 12
Study 10998085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine (2 mg h‐1)
Number of subjects: 12
Study 10998085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 12
Study 8792277 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml of milk containing B. longum B6 grown with lactose
Number of subjects: 15
Study 8792277 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml of milk containing B. longum B6 grown with lactose plus glucose
Number of subjects: 15
Study 8792277 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml of milk containing B. longum ATCC 15708 grown with lactose
Number of subjects: 15
Study 8792277 — intervention group
Group type: COMPARATOR
Intervention: 400 ml of lowfat milk (control)
Number of subjects: 15
Study 1379256 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH-(1-29) high dose (1 mg) sc injections twice daily for 14 days
Number of subjects: 10
Study 1379256 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH-(1-29) low dose (0.5 mg) sc injections twice daily for 14 days
Number of subjects: 10
Study 1379256 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 10
Study 1379256 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH treatment
Number of subjects: 10
Study 6522416 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 12
Study 6522416 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 12
Study 6522416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30711987 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive pharmaceutical interventions
Number of subjects: 50
Study 29972884 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid
Number of subjects: 400
Study 29972884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 26782102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glyceryltrinitrate (GTN) at a maximum tolerable dosage (6.2 ± 1.5 mg/h)
Number of subjects: 21
Study 26782102 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of iloprost (10 μg/mL)
Number of subjects: 21
Study 26782102 — intervention group
Group type: COMPARATOR
Intervention: Control group: intravenous or inhaled sodium chloride (NaCl) 0.9%
Number of subjects: 21
Study 25237048 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXT Step home exercise program
Number of subjects: 180
Study 25237048 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 180
Study 25237048 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (light resistance training)
Number of subjects: 180
Study 22171925 — intervention group
Group type: EXPERIMENTAL
Intervention: Celivarone 50 mg
Number of subjects: 673
Study 22171925 — intervention group
Group type: EXPERIMENTAL
Intervention: Celivarone 100 mg
Number of subjects: 673
Study 22171925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 673
Study 22171925 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 673
Study 22171925 — intervention group
Group type: EXPERIMENTAL
Intervention: Celivarone 300 mg
Number of subjects: 673
Study 22171925 — intervention group
Group type: EXPERIMENTAL
Intervention: Celivarone 600 mg
Number of subjects: 673
Study 19406521 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis indicated in all patients; overall adequacy of prophylaxis according to hospital protocol was 89.1%
Number of subjects: 221
Study 17664057 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory blend rich in polyunsaturated fatty acids (alpha-linolenic acid, 240 mg/d; eicosapentaenoic acid, 120 mg/d; stearidonic acid, 49 mg/d; gamma-linolenic acid, 73 mg/d)
Number of subjects: 30
Study 17664057 — intervention group
Group type: COMPARATOR
Intervention: Inflammatory fat blend (arachidonic acid, 40 mg/d)
Number of subjects: 30
Study 15841721 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter DNA detection in gallbladder samples
Number of subjects: 22
Study 15841721 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter DNA detection in liver samples
Number of subjects: 22
Study 15841721 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of H. pylori specific cytotoxins CagA and VacA
Number of subjects: 22
Study 15841721 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between Helicobacter DNA and IgG antibody responses
Number of subjects: 22
Study 12200947 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled propofol alone
Number of subjects: 66
Study 12200947 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled propofol and target-controlled remifentanil (3 ng mL‐1)
Number of subjects: 66
Study 12200947 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg kg‐1), target-controlled remifentanil (3 ng mL‐1) and target-controlled propofol
Number of subjects: 66
Study 9578242 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (5 weeks) in trained females (17 subjects)
Number of subjects: 88
Study 9578242 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (5 weeks) in trained males (20 subjects)
Number of subjects: 88
Study 9578242 — intervention group
Group type: COMPARATOR
Intervention: Control group females (15 subjects)
Number of subjects: 88
Study 9578242 — intervention group
Group type: COMPARATOR
Intervention: Control group males (10 subjects)
Number of subjects: 88
Study 9578242 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (5 weeks) in trained females and males
Number of subjects: 88
Study 9578242 — intervention group
Group type: COMPARATOR
Intervention: Control group (combined)
Number of subjects: 88
Study 7635409 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFN‐alpha) treatment for 4 months
Number of subjects: 223
Study 7635409 — intervention group
Group type: COMPARATOR
Intervention: Nontreated patients
Number of subjects: 223
Study 7635409 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFN‐alpha) treatment
Number of subjects: 223
Study 2792176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol (20-40 g per day for one month)
Number of subjects: 12
Study 2792176 — intervention group
Group type: COMPARATOR
Intervention: Control period without lactitol
Number of subjects: 12
Study 30878999 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release calcifediol (ERC)
Number of subjects: 429
Study 30878999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 28849265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative chemotherapy (portal vein chemotherapy, intraluminal chemotherapy, and intraperitoneal chemotherapy) plus surgery
Number of subjects: 696
Study 28849265 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 696
Study 28849265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative chemotherapy
Number of subjects: 696
Study 26090383 — intervention group
Group type: EXPERIMENTAL
Intervention: RBTM (rabeprozole 20 mg bid., bismuth subcitrate 120 mg qid, tetracycline 500 mg qid, and metronidazole 250 mg qid)
Number of subjects: 124
Study 26090383 — intervention group
Group type: COMPARATOR
Intervention: RATM (rabeprozole 20 mg bid., amoxicillin 1 g bid., tetracycline 500 mg qid, and metronidazole 250 mg qid)
Number of subjects: 124
Study 26090383 — intervention group
Group type: COMPARATOR
Intervention: RATM
Number of subjects: 124
Study 26090383 — intervention group
Group type: EXPERIMENTAL
Intervention: RBTM
Number of subjects: 124
Study 23497763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron OCAS 50 mg after a high-fat breakfast
Number of subjects: 76
Study 23497763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron OCAS 50 mg after a low-fat breakfast
Number of subjects: 76
Study 23497763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron OCAS 100 mg after a high-fat breakfast
Number of subjects: 76
Study 23497763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron OCAS 100 mg after a low-fat breakfast
Number of subjects: 76